RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA™ for IBS-D Jun 21, 2016
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016 Jun 3, 2016
Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association – European Dialysis & Transplant Association Congress (ERA-EDTA) May 25, 2016
The New York Academy of Sciences Collaborates with Resverlogix to Host Epigenetics Symposium Apr 19, 2016
RedHill Biopharma Reports Successful Final Results of Phase III Study with RHB-105 for H. pylori Infection Mar 9, 2016
RedHill Biopharma Announces Successful PK Study With BEKINDA™ 12 mg and Submission to FDA of IBS-D Phase II Study Protocol Feb 12, 2016
RedHill Biopharma Receives Notice of Allowance of Fifth U.S. Patent Covering RHB-104 Phase III Crohn’s Disease Program Feb 11, 2016
RedHill Biopharma Announces Collaboration with Germany’s Fraunhofer Institute for Oncology Drug RP101 Feb 9, 2016
Resverlogix’s Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal Jan 26, 2016
Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference Nov 10, 2015
